SOPHiA GENETICS Secures $5

PolaSight

PolaSight is a medical technology company developing advanced real-time imaging solutions designed to support surgical decision-making and improve precision during procedures. Our platform aims to help clinicians visualize tissue in real time, enhance workflow efficiency, and enable better patient outcomes. Founded in Switzerland, PolaSight is focused on translating cutting-edge imaging innovation into practical tools for the operating room and beyond.

Verretex

Verretex purchases low quality recycled glass fiber and uses our propriatary technology to regenerate their properties producing high quality glass fiber textiles for reuse in new products.

AlveoliX

Our Vision We aim at changing the way drug development research is done today by providing in-vitro models that reproduce the in-vivo environment in an unprecedented way. These in-vitro models, called organ-on-chips, will make it possible to better predict drugs’ responses in humans than standard in-vitro and in-vivo models and as a consequence to importantly reduce animal testing. Our Mission AlveoliX provides in-vitro solutions based on proprietary and unique organ-on-chip technologies aimed at improving preclinical decision-making and thus reducing drug development costs.

Combioxin SA

Combioxin SA is clinical-stage biotech company developing innovative anti-virulence drugs to treat severe bacterial infections and combat antibiotics resistance

AC Immune

AC Immune SA is a clinical-stage biopharmaceutical company and a global leader in precision prevention for neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, and NeuroOrphan indications driven by misfolded proteins. The Company’s two clinically validated technology platforms, SupraAntigen® and Morphomer®, fuel its broad and diversified pipeline of first- and best-in-class assets, which currently features sixteen therapeutic and diagnostic programs, including five in Phase 2 development and one in Phase 3. AC Immune has a strong track record of securing strategic partnerships with leading global pharmaceutical companies, resulting in substantial non-dilutive funding to advance its proprietary programs and >$4.5 billion in potential milestone payments plus royalties.